乙型肝炎表面抗原
HBeAg
乙型肝炎病毒
病毒学
生物
病毒复制
病毒
RNA干扰
免疫系统
免疫学
核糖核酸
基因
遗传学
作者
Yingying Mao,Xuejun Wang,Wei Ming Hu,Andrew I. Li,Ying Li,Hai Huang,Renhe Yan,Yanling Zhang,Jin‐Long Li,Hongwei Li,Shengqi Wang
标识
DOI:10.1016/j.antiviral.2022.105366
摘要
Chronic hepatitis B virus (HBV) infection remains a global health problem and current treatments are insufficient due to immune tolerance to hepatitis B surface antigen (HBsAg). RNA interference (RNAi) is a more promising approach for antiviral therapy. Here, 17 single artificial microRNAs (amiRNAs) targeting the highly conserved regions of HBV genome were screened to inhibit HBV replication. In addition, we compared three tandem amiRNAs, each containing 3 different amiRNAs, out of which amiRNA135 was selected to be studied in detail. In vitro data showed that amiRNA135 significantly inhibited the replication of different HBV genotypes (including resistant and mutant). In vivo study was carried out by adeno-associated virus 8-mediated gene delivery, we found that the anti-HBV effects of AAV8-amiRNA135 were time and dose-dependent. Serum HBsAg and HBeAg in high dose groups were significantly reduced at 7 days after a single intravenous vector injection, and maintained at low levels throughout a 15-month experiment. Immunohistochemical staining and HBV core particle DNA analysis confirmed that HBV replication in the liver was strongly inhibited by AAV8-amiRNA135. Taken together, our data suggest that AAV8-mediated trimeric amiRNA expression is a promising therapeutic approach for chronic HBV infection.
科研通智能强力驱动
Strongly Powered by AbleSci AI